Sheekooyinka Guusha Cabozantinib ee Daaweynta Caner - AASraw
AASraw waxay soo saartaa Cannabidiol (CBD) budada iyo Hemp Saliida Muhiimka ah!

Cabozantinib

 

    1. Sharaxaadda 'Cabozantinib'
    2. Mashruuca Cabozantinib ee Waxqabadka
    3. Saamaynta Cabozantinib
    4. Horumarka ugu dambeeya ee Cabozantinib
    5. Sheekooyinka Guusha Daaweynta Cabozantinib
    6. Summary

 

Cabozantinib Description

Cabozantinib (CAS:849217-68-1) waxaa loo isticmaalaa in lagu daaweeyo kansarka kalyaha ee horumarsan, mararka qaarna waxaa lagu daraa daawo kale oo la yiraahdo nivolumab. Cabozantinib sidoo kale waxaa loo isticmaalaa in lagu daaweeyo kansarka beerka ku dhaca dadka horay loogu daweeyay sorafenib. Cabozantinib waxaa loo isticmaalaa in lagu daaweeyo kansarka tayroodhka ee ku faafay qaybaha kale ee jirka. Cabozantinib sidoo kale waxaa loo isticmaali karaa ujeedooyin aan ku xusnayn tilmaamahan dawadan.

 

Cabozantinib Farsamooyinka Ficil

Daaweynta la beegsaday waa natiijada qiyaastii 100 sano oo cilmi baaris ah oo loogu talagalay fahamka faraqa u dhexeeya unugyada kansarka iyo unugyada caadiga ah. Ilaa hadda, daaweynta kansarku waxay diiradda saartay ugu horreyntii in la dilo unugyada si dhakhso leh u kala qaybiya maxaa yeelay hal muuqaal oo ka mid ah unugyada kansarku waa inay si dhakhso leh u qaybsamaan. Nasiib darrose, qaar ka mid ah unugyadeenna caadiga ah ayaa si dhakhso leh u kala qaybsama, taas oo keenta waxyeelooyin badan

Daaweynta Targeted wuxuu ku saabsan yahay aqoonsiga sifooyinka kale ee unugyada kansarka. Cilmi-baarayaashu waxay raadiyaan kala duwanaansho khaas ah unugyada kansarka iyo unugyada caadiga ah. Macluumaadkan waxaa loo isticmaalaa in lagu abuuro daaweyn la beegsado si looga hortago unugyada kansarka iyada oo aan waxyeello unugyada caadiga ah, taas oo keeneysa saameyno yar. Nooc kasta ee daaweynta la beegsanayo wax yar ayuu u shaqeeyaa laakiin dhammaantood waxay faragalinayaan awoodda unugyada kansarka si ay u koraan, u qaybiyaan, dayactiraan iyo / ama ula xiriiraan unugyada kale.

Waxaa jira noocyo kala duwan oo ah daaweyn la beegsaday, oo lagu qeexay saddex qaybood oo ballaaran. Qaar ka mid ah daaweynta la beegsaday ayaa diiradda saaraya qaybaha gudaha iyo shaqada unugyada kansarka. Daawooyinka la beegsaday waxay isticmaalaan unugyada yaryar ee unugyada yaryar ee unugyada unugyada gala unugyada unugyada unugyada yaryar ee unugyada unugyada unugyada unugyada unugyada unugyada unugyada yaryar. Waxaa jira dhowr nooc oo ah daaweyn la beegsan oo diiradda saara qaybaha gudaha ee unugyada. Daawooyinka kale ee la beegsanayo ee la beegsanayo waxay beegsanayaan qolalka dib u habeeynaya ee ku yaal dibadda qolka. Daawooyinka lagu beegsanayo soo dhaweeyayaasha ayaa sidoo kale loo yaqaannaa difaaca monoclonal. Niyadjirayaasha Antiangiogenesis waxay bartilmaameedaan xididdada dhiigga ee bixiya oksijiinka unugyada, taasoo ugu dambeyntii keenta unugyada inay gaajooto.

Cabozantinib waa daaweyn la bartilmaameedsaday oo bartilmaameedsanaya kuna xidhan tyrosine kinase receptors iyo xakameynaya waxqabadyada kinase badan ee tyrosine, oo ay ku jiraan RET, MET, iyo VEGF dusha sare ee unuga. Adoo ku xiraya qaboojiyayaashan, cabozantinib wuxuu xannibaa waddooyin muhiim ah oo dhiirrigeliya qaybinta unugyada

Cilmi-baaris ayaa sii socota si loo ogaado kansarrada laga yaabo in lagu daweeyo daawooyinka la beegsanayo iyo in la ogaado bartilmaameedyo dheeri ah oo loogu talagalay noocyo badan oo kansar ah.

 

Cabozantinib Waxyaabaha kale ee saameynaya

Hel gargaar caafimaad oo degdeg ah haddii aad leedahay calaamado falcelin xasaasiyad: xoqitaan; neefta oo adkaata; barar wejigaaga, dibnaha, carrabka, ama cunaha.

Cabozantinib wuxuu sababi karaa dalool (dalool ama jeex) ama feedho (marin marin aan caadi ahayn) calooshaada ama xiidmaha. Wac dhakhtarkaaga haddii aad leedahay calool xanuun daran, ama haddii aad dareento inaad ku mergayso oo xiiqayso markii aad wax cunayso ama wax cabayso.

Wac dhakhtarkaaga isla markiiba haddii aad leedahay:

Headache Madax xanuun daran, aragga oo xumaada, qoorta ama dhagaha;

▪ Matag, shuban, ama caloosha oo daran oo socota;

▪ Barar gacmahaaga, gacmahaaga, lugahaaga, ama cagahaaga;

B Nabar nabar ama dhiig bax (sanka oo dhiig ka yimaado, ciridka oo dhiig baxa, dhiigbaxa caadada oo culus, ama dhiig bax aan joogsan doonin)

St Saxaro dhiig leh ama daahay ah, ku qufac dheecaan dhiig leh ama matag u eg qaxwaha;

▪ Jaundice (maqaarka ama indhaha oo hurdi noqda);

▪ Xanuun, nabarro, dhiig bax, ama finan daran oo ku dhaca calaacalaha gacmahaaga ama cagahaaga;

Jahwareer, dhibaatooyinka fikirka, daciifnimo, aragga oo isbedela, suuxdin;

Feeling Dareen madax-fudud, sida laga yaabo inaad dhaafto;

▪ Daanka xanuun ama kabuubis, ciridka oo guduudan ama barara, ilkaha oo dabacsan, ama bogsiin gaabis ah shaqada ilkaha kadib;

Cell Unugga dhiigga cad oo hooseeya ayaa tiriya - qandho, nabarro afka ah, nabarro maqaarka, dhuun xanuun, qufac, neefsashada oo dhib ku ah;

Problems Dhibaatooyinka qanjidhada adrenal - lallabbo, matag, daal fara badan, wareer, daciifnimo, miyir beelid; ama

▪ Calaamadaha istaroogga ama xinjirowga dhiigga - kabuubis lama filaan ah ama daciifnimo dhinac jirkaaga ka mid ah, dhibaatooyin xagga aragtida ama dheelitirka ah, dhibaato hadalka ama fahamka waxa lagugu sheego, xabad xanuun, neefsashada oo dhib ah, barar ama xanuun gacanta ama lugta ah .

Qiyaastaada mustaqbalka ee cabozantinib waa la daahi karaa ama si joogto ah ayaa loo joojin karaa haddii aad leedahay waxyeelo gaar ah.

AASraw waa soo saaraha xirfadlaha ah ee Cabozantinib.

Fadlan halkan guji si aad u hesho macluumaadka xigashada: Nala soo xiriir

 

Waxyeellooyinka caamka ah waxaa ka mid noqon kara:

Pain Xanuun caloosha, lallabbo, matag, rabitaanka cuntada oo yaraada, shuban, calool istaag;

▪ Xanuun, casaan, barar, ama nabarro ku dhaca afkaaga ama cunaha;

Dhibaato hadalka, isbedelka dhadhanka;

Symptoms Calaamadaha hargabka sida sanka oo xirma, hindhiso, cuna xanuun, qufac;

▪ finan;

Xanuun ku dhaca murqahaaga, lafahaaga, iyo kala-goysyadaada;

Tests Baaritaanno shaqo oo aan caadi ahayn oo beerka ah ama baaritaanno kale oo dhiig ah;

Tired Dareen dareemo;

Ight Miisaan lumis; ama

Color Midabka timuhu inuu khafiif noqdo.

Tani ma aha liis dhammeystiran oo saameyno kale ah iyo qaar kale ayaa dhici kara. Wac dhakhtarkaaga wixii talo bixin ah ee ku saabsan dhibaatooyinka soo raaca. Waxaad u sheegi kartaa saameynahaaga FDA ee 1-800-FDA-1088.

 

Horumarkii Ugu Dambeeyay Ee Cabozantinib 

Cabozantinib waxaa siiyay xaaladda daroogada agoonta Maamulka Cuntada iyo Dawooyinka ee Mareykanka (FDA) bishii Nofeembar 2010 iyo Febraayo 2017.

Exelixis ayaa codsi cusub oo dawooyin ah u gudbisay FDA qeybtii hore ee 2012 iyo bishii Noofambar 29, 2012 cabozantinib qaabkeeda kaabsulka ah waxaa oggolaansho suuqgeyn ah ka heshay FDA-da Mareykanka oo magaceeda la yiraahdo Cometriq si loogu daaweeyo bukaanada qaba kansarka qanjirka 'thyroid'. lagu ansixiyay Midowga Yurub isla ujeeddadaas 2014.

Bishii Maarso 2016 Exelixis waxay ruqsad u siisay Ipsen xuquuqda adduunka (oo ka baxsan Mareykanka, Kanada, iyo Japan) inay u suuq geyso cabozantinib.

Natiijooyinka tijaabada 'Exelixis' Wejiga III ee tijaabada daawada ee kilyaha kansarka waxaa lagu daabacay NEJM sanadkii 2015. Bishii Abriil 2016 FDA waxay ogolaatay oggolaanshaha suuqgeynta sameynta kaniiniga oo ah xariiq labaad oo daaweynta kelyaha kansarka isla sidaasna waxaa lagu ansixiyay Midowga Yurub bishii Sebtember ee sanadkaas.

Bishii Diseembar 2017, FDA waxay oggolaatay cabozantinib (Cabometyx, Exelixis, Inc.) si loogu daaweeyo dadka qaba kansarka kelyaha ee kelyaha (RCC). Ansixinta waxay ku saleysneyd xogta laga helay CABOSUN (NCT01835158), oo la kala soocayo, wejiga labaad ee daraasad badan oo daraasado badan ah oo ka socda kaqeybgalayaasha 157 oo leh dhexdhexaad iyo khatar liidata oo aan horey loo daaweynin.

Bishii Janaayo 2019, FDA ayaa ogolaatay cabozantinib (Cabometyx, Exelixis, Inc.) oo loogu talagalay dadka qaba kansarka cagaarshowga (HCC) ee horey loogu daaweeyay sorafenib. Ansixinta waxay ku saleysneyd CELESTIAL (NCT01908426), oo la kala soocay (2: 1), laba-indhoole, xakamaynta placebo, tijaabooyin badan oo kaqeybgalayaal ka tirsan kaqeybgalayaasha HCC oo horey uhelay sorafenib oo lahaa cilladaha beerka.

Cabozantinib waxaa lagu baarayaa waxtarka daaweynta ee nooca neurofibromatosis nooca 1.

Maamulka Cuntada iyo Dawooyinka (FDA) ayaa dhawaan ansixiyay cabozantinib daaweynta kansarka cagaarshowga hepatocellular ee bukaanada horay u helay sorafenib.

Cabozantinib waa kahortaga tyrosine kinases ee kahortaga MET, VEGFR, iyo AXL.Receptor tyrosine kinases ayaa door muhiim ah kaqaata shaqooyinka caadiga ah ee unugyada iyo hababka cudurada, oo ay kujiraan oncogenesis, metastasis, tumor angiogenesis, iyo buro microenvironment.

FDA ayaa markii hore ogolaatay cabozantinib daaweynta medullary kansarka tayroodh. Markii dambe, FDA waxay oggolaatay isticmaalkeeda kansarka unugyada kelyaha.

 

Sheekooyinka Guusha Daaweynta Cabozantinib 

Sheekada 1aad: Cabozantinib Waxa Lagu Daaweeyaa Daaweynta Safka Koowaad ee Carcinoma Kelyaha Sare

Bishii Diseembar 19, 2017, Maamulka Cuntada iyo Dawooyinka ee Mareykanka (FDA) ayaa oggolaansho joogto ah siiyay cabozantinib (Cabometyx) si loogu daaweeyo bukaannada qaba kansarka kelyaha ee ugu dambeeyay (RCC).

FDA ayaa horey u ansixisay cabozantinib sanadkii 2016 si loogu daaweeyo bukaanada qaba RCC-da horumarsan ee horey uhelay daaweynta antiangiogenic. Ansixinta maanta waxay bixineysaa daaweynta qaabka safka koowaad.Cabozantinib

Oggolaanshahani wuxuu ku salaysnaa xogta laga helay tijaabada CABOSUN, oo la kala soocay, waji furan calaamadda labaad ee daraasad badan oo bukaanno ah 157 bukaanno dhexdhexaad ah iyo khatar liidata oo aan hore loo daaweynin RCC. Bukaanku waxay heleen cabozantinib (n = 79) 60 mg afka ah maalin kasta ama sunitinib (Sutent) (n = 78) 50 mg afka ah maalin kasta (4 usbuuc oo daaweyn ah oo ay ku xigto 2 usbuuc oo fasax ah) ilaa cudurka uu ka sii socdo ama sun aan la aqbali karin. Qiyaasta badbaadada dhexdhexaadka ah ee bilaashka ah (sida lagu qiimeeyay gudiga dib u eegista shucaaca madaxa banaan ee indho la'aanta ah) ee loogu talagalay bukaanada qaata cabozantinib waxay ahayd bilooyin 8.6 (95% isku-kalsoonida kalsoonida [CI] = 6.8-14.0) marka la barbardhigo bilaha 5.3 (95% CI = 3.0-8.2) loogu talagalay bukaannada qaata sunitinib (halista saamiga = 0.48; 95% CI = 0.31-0.74; P = .0008).

Inta badan la soo sheego (≥ 25%) falcelinta xun ee barnaamijka kilizantinib waa shuban, daal, lallabbo, rabitaanka cuntada oo yaraada, dhiig kar, palmar-plantar erythrodysesthesia, miisaan lumis, matag, dysgeusia, iyo stomatitis.

Fasalka ugu badan ee falcelinta xun ee 3-4 (≥ 5%) ee bukaanada lagu daaweeyo cabozantinib ee CABOSUN waxay ahaayeen dhiig kar, shuban, hyponatremia, hypophosphatemia, palmar-plantar erythrodysesthesia, daal, ALT oo kordhay, rabitaanka cuntada oo yaraaday, stomatitis, xanuun, hypotension, iyo syncope. Qiyaasta lagu taliyey ee cabozantinib waa 60 mg afka ah, hal mar maalintii.

Cabozantinib sidoo kale waa loo oggol yahay daaweynta dawee kansarka qanjirka tayroodh waxaana lagu suuq geeyay magaca ganacsiga Cometriq. Cometriq iyo Cabometyx waxay leeyihiin qaabab kala geddisan oo aan la isku beddeli karin.

 

Story 2: Cabozantinib Dawee kansarka 'Medullary Thyroid Cancer'

FDA waxay ansixisay cabozantinib (Cometriq) si loogu daaweeyo kansarka qanjirka 'metastatic medullary thyroid cancer' (MTC) bishii Nofeembar 2012. Waxay ku saleysneyd natiijooyinka ka soo baxay caalami, tiro badan, la kala soocay, laba-indhoole, tijaabo la xakameeyay oo ay ku jiraan 330 maadooyin. Kaqeybgalayaashu waxay ubaahanyihiin inay soo bandhigaan cudurka horusocodka 14 bilood gudahood kahor gelitaanka daraasadda, taas oo lagu xaqiijiyay iyada oo loo marayo guddiga dib-u-eegista shucaaca madaxbanaan ama dhakhtarka daaweynta.

Bukaannada ayaa loo kala soocay si ay u helaan mid ka mid ah cabozantinib 140 mg ama placebo hadal ahaan hal mar maalintii illaa cudurka horusocodka ama sunta aan loo dulqaadan karin. Kala soocida ayaa loo kala saaray iyadoo loo eegayo da'da <65 sano vs> 65 sano iyo adeegsiga hore ee tyrosine kinase inhibitor.Cabozantinib

Ujeeddooyinka aasaasiga ahi waxay ahaayeen badbaado horumar la'aan ah (PFS), jawaab ujeedo (AMA), iyo muddada jawaabta ee shaqaalaynta shuruudaha RECIST. Bukaannada ku jira kooxda 'cabozantinib' waxay sii dheereeyeen PFS marka loo eego kuwa qaata placebo (P <.0001). Gaar ahaan, dhexdhexaadka PFS ee gacanta cabozantinib wuxuu ahaa 11.2 bilood iyo dhexdhexaadka PFS ee gacanta placebo wuxuu ahaa 4.0 bilood.

Kaliya bukaannada qaata cabozantinib waxay la kulmeen jawaab celin (27% vs 0; P <.0001). Intaas waxaa sii dheer, muddada dhexdhexaadka ah ee AMA waxay ahayd 14.7 bilood kuwa loogu daweeyay daroogada. Ma jirin farqi weyn oo u dhexeeya guud ahaan badbaadada oo lagu arkay hubka dhexdooda.

Falanqaynta meta-iyo 2019 ee qiimeynta faa'iidada cabozantinib iyo vandetanib ee bukaanada Adeegga Caafimaadka Qaranka ee England, Tappenden et al. Gabagabeeyay.

"Tijaabooyinka la aqoonsaday waxay soo jeedinayaan in cabozantinib iyo vandetanib ay horumariyaan PFS in ka badan placebo; si kastaba ha noqotee, faa'iidooyinka OS ee muhiimka ah lama muujin. Falanqaynta dhaqaalaha waxay muujineysaa in tirada calaamadeynta EU-da, ICERs [saamiga waxtarka waxtarka leh ee kordhinta] ee cabozantinib iyo vandetanib ay yihiin> £ 138,000 halkii QALY (sanad nololeed oo tayo leh). Xaddidaadda EU-da (Midowga Yurub) -label ee tirada, ICER ee vandetanib waxaa la filayaa inay ahaato> £ 66,000 halkii QALY laga helo. ”

 

Story 3: Daaweynta Cabozantinib Cudurka Kansarka 'Hepatocellular Carcinoma'

Bishii Janaayo 2019, FDA waxay ansixisay kiniiniyada 'cabozantinib' ee bukaannada qaba kansarka hepatocellular (HCC) oo horay loogu daweeyay sorafenib. Ansixinta waxay ku saleysneyd natiijooyinka tijaabada CELESTIAL.

Marka la kala sooco (2: 1), laba-indhoole, indho-indheyn, xakameyn placebo, tijaabooyin fara badan, bukaanada waxaa loo kala soocay cabozantinib 60 mg afka ah hal mar maalintii (n = 470) ama placebo (n = 237) ilaa waqtiga cudurka uu sii socdo ama aan la aqbali karin sumoobo.Cabozantinib

Bartilmaameedka koowaad wuxuu ahaa OS. PFS iyo ORR, oo ay qiimeeyeen baarayaasha isticmaalaya RECIST 1.1, ayaa sidoo kale la cabiray. Isticmaalka Cabozantinib wuxuu la xiriiray OS dhexdhexaad ah oo ah 10.2 bilood (95% CI: 9.1-12.0) vs 8 bilood (95% CI: 6.8-9.4) kuwa qaata placebo (HR 0.76; 95% CI: 0.63, 0.92; P = )0049) Dhexdhexaadiyaha PFS wuxuu ahaa 5.2 bilood (4.0-5.5) gacanta cabozantinib marka la barbar dhigo bilaha 1.9 (1.9-1.9) ee gacanta placebo (HR 0.44; 95% CI, 0.36, 0.52; P <.001). ORR wuxuu ahaa 4% (95% CI, 2.3, 6.0) kuwa qaata cabozantinib vs 0.4% (95% CI, 0.0, 2.3) kuwa qaada placebo.

Fasallada 3 ama 4 dhacdooyinka xun ayaa ka sarreeya bukaanada qaata cabozantinib (68%) marka loo eego kuwa qaadanaya placebo (36%).

Qorayaasha tijaabada CELESTIAL waxay ku soo gabagabeeyeen waxyaabahan soo socda: “Bukaanada horey loogu daaweeyey kansarka sare ee hepatocellular carcinoma, daaweynta cabozantinib waxay keentay guud ahaan badbaado iyo badbaado horumar la'aan ah marka loo eego placebo. Qiyaasta dhacdooyinka xun ee fasalka sare ee kooxda cabozantinib waxay ahayd ugu yaraan laba jeer oo lagu arkay kooxda placebo. ”

 

Summary

Cabozantinib waa daawada loo yaqaan 'tyrosine kinase inhibitor' loo isticmaalo in lagu daaweeyo kansarka unugyada kelyaha ee horumarsan, kansarka qanjirka 'hepatocellular carcinoma', iyo kansarka qanjirka 'thyroid' Cabozantinib waxaa markii ugu horreysay la ansixiyay 2012 waana mid aan takhasus u lahayn tyrosine kinase inhibitor. Waxaa markii hore lagu ansixiyay Mareykanka iyada oo loo marayo magaca calaamadda Cometriq, kaas oo loogu talagalay daaweynta kansarka qanjirka 'metastatic medullary'. 2016, qaabaynta kaabsoosha (Cabometyx) ayaa loo oggolaaday daaweynta kansarka kalyaha ee kelyaha, isla qaabkan ayaa helay oggolaansho dheeri ah oo laga helo labada waddan ee Mareykanka iyo Kanada sannadka 2019 ee daaweynta kansarka 'hepatocellular carcinoma' ee bukaanno horay loo daweeyay.

AASraw waa soo saaraha xirfadlaha ah ee Cabozantinib.

Fadlan halkan guji si aad u hesho macluumaadka xigashada: Nala soo xiriir

 

Tixraaca

[1] Choueiri TK, Escudier B, Powles T, iyo al. Cabozantinib oo ka soo horjeedda everolimus oo ku jirta unugyada kansarka kalyaha ah ee horumarsan (METEOR): natiijooyinka kama dambaysta ah ee laga soo qaatay kala-sooc la'aanta, calaamadda furan, tijaabada wejiga 3. Lancet Oncol. 2016; 17: 917–27.

[2] Tappenden P, Carroll C, Hamilton J, et al. Cabozantinib iyo vandetanib oo loogu talagalay kansarka tayroodhka maxalliga ah ee heer sare ama metastatic medullary: dib u eegis nidaamsan iyo qaab dhaqaale. Qiimaynta Technol Health. 2019; 23: 1-144.

[3] George DJ, Hessel C, Halabi S, iyo al. Cabozantinib iyo sunitinib oo loogu talagalay bukaannada aan la daaweyn ee leh kansarka unugyada kalyaha ee horumarsan ee khatarta dhexe ama liidata: Falanqaynta koox hoosaadka ee isbahaysiga A031203 CABOSUN. Dhakhtarka kansarka. 2019; 24: 1-5.

[4] Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ , Salgia R: Waxqabadka XL184 (Cabozantinib), oo ah afka loo yaqaan 'tyrosine kinase inhibitor', bukaanka qaba kansarka qanjirka 'medullary' J Clin Oncol. 2011 Jul 1; 29 (19): 2660-6. doi: 10.1200 / JCO.2010.32.4145. Epub 2011 Laga yaabaa 23.

[5] Abou-Alfa GK, Meyer T, Cheng AL, iyo al. Cabozantinib oo kujira bukaanka qaba hepatocellular carcinoma. N Engl J Med. 2018; 379: 54-63.

[6] Maamulka Cuntada iyo Dawooyinka ee Mareykanka. FDA waxay oggolaatay cabozantinib oo loogu talagalay cudurka kansarka 'hepatocellular carcinoma'. Waxaa laga heli karaa: https://www.fda.gov/drugs/fda-approves-cabozantinib-hepatocellular-carcinoma Laga helay Ogosto 28, 2019.

[7] Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, Adiga A, Laird AD, Engst S, Lee L, Lesch J, Chou YC , Joly AH: Cabozantinib (XL184), sheeko-yaqaan 'MET' iyo 'VEGFR2 inhibitor', ayaa si isku mid ah u xakameynaya metastasis, angiogenesis, iyo koritaanka burooyinka. Kansarka Mol Ther. 2011 Dec; 10 (12): 2298-308. doi: 10.1158 / 1535-7163.MCT-11-0264. Epub 2011 Sep 16.

[8] "Daawada kansarka qanjidhka 'cabozantinib' waxay dheereysaa PFS". Laga keydiyay asalka 2012-04-02. Waxaa dib loo helay 24-kii Oktoobar 2011.

[9] "Cabozantinib Agoomaha Magacaabista iyo Ansixinta". Maamulka Cuntada iyo Dawooyinka ee Mareykanka (FDA). 29 Nofeembar 2010. La soo celiyey 11 Nofeembar 2020.

0 jecel yahay
6555 Views

Waxaa kaloo laga yaabaa

Comments are closed.